The rise and fall of 23andMe

23andMe was one of the hottest startups of the 2000s, once valued at $6 billion. The company's DNA test kits became a viral sensation. But today, it has lost 98% of its value and is on the verge of being delisted from the Nasdaq after board members resigned, citing frustration with founder and CEO Anne Wojcicki's "strategic differences" in her vision for the company. Meanwhile, 23andMe is sitting on the world's largest genetic database that it once hoped to leverage for drug development.